- Trial phase
- Phase 3
- Time to market
- Takeda plans to submit marketing applications to the FDA, EMA and Japan's PMDA during its fiscal year 2026, which ends March 31, 2027. If submissions occur by that date, potential US approval would likely come 10-12 months later, putting a possible launch in late 2027 or 2028.
- Why 3/10
- No hard dated binary catalyst exists in the next ~12 months. Takeda plans to submit regulatory applications in fiscal year 2026 (by March 31, 2027), but no BLA/NDA has been filed and no PDUFA date is set. TAK is a large, diversified pharma (approximately $30B revenue) with many pipeline drugs, so TAK-881 is a modest contributor rather than a make-or-break asset.
Watch for Takeda's regulatory submissions for TAK-881 in the US, EU and Japan, expected by the end of its fiscal year (March 31, 2027). A submitted BLA would trigger a 10-12 month FDA review cycle and set a PDUFA date, creating a future binary catalyst. Also monitor the Phase 3 CIDP study (TAK-881-3003, MIgGRATE) for potential label expansion. For a company of Takeda's size, none of these events alone will dramatically move the stock.
Price Chart
Executive Summary
TAK-881 is Takeda's next-generation subcutaneous immunoglobulin therapy for primary immunodeficiency diseases (PIDD). A 20% antibody solution co-formulated with hyaluronidase, it delivers the same immune protection as Takeda's existing product HYQVIA (SCIG 10%) but in half the volume and with roughly 43% shorter infusion time. The pivotal Phase 2/3 IgGNITE trial met its primary PK comparability endpoint, and detailed results were presented at ESID 2026 on October 14, 2026. Takeda expects to submit for US, EU and Japanese approval during its fiscal year 2026 (by March 31, 2027). The drug is also being studied for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Takeda is a large-cap pharma with revenue near $30B, making TAK-881 one of many pipeline assets rather than a single-stock binary event.
How It Works
TAK-881 is a concentrated (20%) solution of antibodies (immunoglobulin G) collected from human plasma, mixed with an enzyme (hyaluronidase) that temporarily breaks down a barrier under the skin so a larger volume can be absorbed. It is infused under the skin to replace missing antibodies in patients with primary immunodeficiency diseases (PIDD). At 20% concentration, it delivers the same dose of antibodies in half the fluid volume of Takeda's current product HYQVIA (which is 10%), cutting infusion time significantly.
Trial Status
The pivotal Phase 2/3 IgGNITE trial (TAK-881-3001, NCT05755035) in 65 patients with PIDD has been completed. Results were presented at ESID 2026 on October 14, 2026, meeting the primary endpoint of pharmacokinetic comparability to HYQVIA. A Phase 3 long-term safety extension (TAK-881-3002, NCT06076642) is ongoing. A separate Phase 3 trial for CIDP (TAK-881-3003, NCT06747351, the MIgGRATE study) is recruiting.
The Two-Sided Case
Upcoming Catalysts
- Regulatory submission (BLA/NDA/MAA) to FDA, EMA and/or PMDA -- expected in fiscal year 2026 (by March 31, 2027)
- Phase 3 long-term safety extension study TAK-881-3002 data readout
- Phase 3 CIDP study TAK-881-3003 (MIgGRATE) data readout
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report